Simone Meijer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Simone Meijer has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Merve Karacaoglu
Leiden Univ, Hlth Med & Neuropsychol Unit, Leiden, Netherlands
4 shared publications Andrea W. M. Evers
Health, Medical and Neuropsychology Unit Leiden University Leiden The Netherlands
3 shared publications- Andrea Walburga Maria Evers
Faculty of Industrial Design Engineering, Delft University of Technology
3 shared publications - Dieuwke Swaantje Veldhuijzen
Health, Medical and Neuropsychology unit, Faculty of Social and Behavioural Sciences, Leiden University, the Netherlands
3 shared publications Henriët van Middendorp
Health, Medical and Neuropsychology Unit Leiden University Leiden The Netherlands
3 shared publicationsKaya J. Peerdeman
Health, Medical and Neuropsychology Unit Leiden University Leiden The Netherlands
3 shared publications
Latest Publications
- Open Access
- 12 March 2026
- Published by Wiley in European journal of pain
- Vol. 30 (3) , e70248
Can Nocebo Effects Be Reduced via Open‐ and Closed‐Label Counterconditioning?
Background: The overwhelming evidence of nocebo effects adversely affecting the experience of physical symptoms, such as pain, puts emphasis on the study of possible strategies to reduce nocebo effects. Counterconditioning, during which a previously conditioned effect is reversed, has been shown to be a possible promising strategy in a previous study in an open‐label design, in which people were informed about the use of inert treatments and the counterconditioning procedure. However, it is unclear whether open‐label counterconditioning is as effective as closed‐label procedures in comparison to extinction. Methods: In a randomised controlled trial, we investigated in 66 healthy female participants whether conditioned nocebo effects on pressure pain can be reduced via open‐label counterconditioning, closed‐label counterconditioning, or extinction. Results: A significant reduction of nocebo effects was found after open‐label counterconditioning ( d = 1.13), closed‐label counterconditioning ( d = 0.69), and extinction ( d = 0.66). Open‐label counterconditioning was more effective than extinction ( d = 0.85), reversed the nocebo effect, and also resulted in a placebo effect. Closed‐label counterconditioning was more effective than extinction ( d = 0.45) in the sensitivity analyses of nocebo responders only. Finally, larger placebo expectancies predicted a higher response to the open‐ and closed‐label counterconditioning procedures, but not extinction. Conclusions: These results show that particularly open‐label counterconditioning is an effective method to modulate nocebo effects on pressure pain. This provides promise in designing non‐deceptive learning‐based treatments to reduce nocebo effects in diverse patient groups, including chronic pain disorders. Significance Statement: Few studies have investigated the efficacy open‐label counterconditioning to reduce nocebo effects or have compared it to deceptive reduction strategies. The current study demonstrates that open‐label counterconditioning is as effective as more deceptive nocebo‐reducing strategies and may thus be a promising new method for reducing nocebo effects in a non‐deceptive and ethical manner. Results can be helpful while designing learning‐based treatments to reduce nocebo effects in patients with, for example, chronic pain disorders. Trial Registration: ClinicalTrials.gov identifier: NCT05284383
- 12 March 2026
- Published by Wiley in European journal of pain
- Vol. 30 (3) , e70248
Open AccessCan Nocebo Effects Be Reduced via Open‐ and Closed‐Label Counterconditioning?
Background: The overwhelming evidence of nocebo effects adversely affecting the experience of physical symptoms, such as pain, puts emphasis on the study of possible strategies to reduce nocebo effects. Counterconditioning, during which a previously conditioned effect is reversed, has been shown to be a possible promising strategy in a previous study in an open‐label design, in which people were informed about the use of inert treatments and the counterconditioning procedure. However, it is unclear whether open‐label counterconditioning is as effective as closed‐label procedures in comparison to extinction. Methods: In a randomised controlled trial, we investigated in 66 healthy female participants whether conditioned nocebo effects on pressure pain can be reduced via open‐label counterconditioning, closed‐label counterconditioning, or extinction. Results: A significant reduction of nocebo effects was found after open‐label counterconditioning ( d = 1.13), closed‐label counterconditioning ( d = 0.69), and extinction ( d = 0.66). Open‐label counterconditioning was more effective than extinction ( d = 0.85), reversed the nocebo effect, and also resulted in a placebo effect. Closed‐label counterconditioning was more effective than extinction ( d = 0.45) in the sensitivity analyses of nocebo responders only. Finally, larger placebo expectancies predicted a higher response to the open‐ and closed‐label counterconditioning procedures, but not extinction. Conclusions: These results show that particularly open‐label counterconditioning is an effective method to modulate nocebo effects on pressure pain. This provides promise in designing non‐deceptive learning‐based treatments to reduce nocebo effects in diverse patient groups, including chronic pain disorders. Significance Statement: Few studies have investigated the efficacy open‐label counterconditioning to reduce nocebo effects or have compared it to deceptive reduction strategies. The current study demonstrates that open‐label counterconditioning is as effective as more deceptive nocebo‐reducing strategies and may thus be a promising new method for reducing nocebo effects in a non‐deceptive and ethical manner. Results can be helpful while designing learning‐based treatments to reduce nocebo effects in patients with, for example, chronic pain disorders. Trial Registration: ClinicalTrials.gov identifier: NCT05284383
- Open Access
- 17 April 2023
- Published by Wolters Kluwer Health in The Clinical Journal of Pain
- Vol. 39 (6) , 259-269
Susceptibility to Nocebo Hyperalgesia, Dispositional Optimism, and Trait Anxiety as Predictors of Nocebo Hyperalgesia Reduction
Objectives: The current paper explores the psychological predictors of nocebo hyperalgesia and whether the reduction of nocebo hyperalgesia can be predicted by susceptibility to nocebo hyperalgesia and psychological characteristics. Methods: To this end, nocebo effects on pressure pain were first experimentally induced in 83 healthy female participants through conditioning with open-label instructions about the pain-worsening function of a sham TENS device, to assess susceptibility to nocebo hyperalgesia. Participants were then randomized to one out of two nocebo-reduction conditions (counterconditioning/extinction), or to continued nocebo conditioning (control), each combined with open-label instructions about the new sham device function. Dispositional optimism, trait and state anxiety, pain catastrophizing, fear of pain, and body vigilance were assessed at baseline. Results: showed that lower optimism and higher trait anxiety were related to a stronger induction of nocebo hyperalgesia. Moreover, a stronger induction of nocebo hyperalgesia and higher trait anxiety predicted a larger nocebo reduction across interventions. Also, nocebo hyperalgesia and optimism moderated the effects of the nocebo-reduction interventions, whereby larger nocebo hyperalgesia and lower optimism were associated with a larger nocebo reduction after counterconditioning, compared to control, and also compared to extinction for larger nocebo hyperalgesia. Discussion: Our findings suggest that open-label conditioning leads to stronger nocebo hyperalgesia when trait anxiety is high and dispositional optimism is low, while these psychological characteristics along with larger nocebo hyperalgesia also predict open-label counterconditioning to be an effective nocebo-reduction strategy. Susceptibility to nocebo hyperalgesia, trait anxiety, and dispositional optimism might be indicators of a flexible pain regulatory system.
- 17 April 2023
- Published by Wolters Kluwer Health in The Clinical Journal of Pain
- Vol. 39 (6) , 259-269
Open AccessSusceptibility to Nocebo Hyperalgesia, Dispositional Optimism, and Trait Anxiety as Predictors of Nocebo Hyperalgesia Reduction
Objectives: The current paper explores the psychological predictors of nocebo hyperalgesia and whether the reduction of nocebo hyperalgesia can be predicted by susceptibility to nocebo hyperalgesia and psychological characteristics. Methods: To this end, nocebo effects on pressure pain were first experimentally induced in 83 healthy female participants through conditioning with open-label instructions about the pain-worsening function of a sham TENS device, to assess susceptibility to nocebo hyperalgesia. Participants were then randomized to one out of two nocebo-reduction conditions (counterconditioning/extinction), or to continued nocebo conditioning (control), each combined with open-label instructions about the new sham device function. Dispositional optimism, trait and state anxiety, pain catastrophizing, fear of pain, and body vigilance were assessed at baseline. Results: showed that lower optimism and higher trait anxiety were related to a stronger induction of nocebo hyperalgesia. Moreover, a stronger induction of nocebo hyperalgesia and higher trait anxiety predicted a larger nocebo reduction across interventions. Also, nocebo hyperalgesia and optimism moderated the effects of the nocebo-reduction interventions, whereby larger nocebo hyperalgesia and lower optimism were associated with a larger nocebo reduction after counterconditioning, compared to control, and also compared to extinction for larger nocebo hyperalgesia. Discussion: Our findings suggest that open-label conditioning leads to stronger nocebo hyperalgesia when trait anxiety is high and dispositional optimism is low, while these psychological characteristics along with larger nocebo hyperalgesia also predict open-label counterconditioning to be an effective nocebo-reduction strategy. Susceptibility to nocebo hyperalgesia, trait anxiety, and dispositional optimism might be indicators of a flexible pain regulatory system.
- Open Access
- 3 April 2023
- Published by Wiley in European journal of pain
- Vol. 27 (7) , 831-847
Efficacy of open‐label counterconditioning for reducing nocebo effects on pressure pain
BackgroundNocebo effects can adversely affect the experience of physical symptoms, such as pain and itch. Nocebo effects on itch and pain have shown to be induced by conditioning with thermal heat stimuli and reduced by counterconditioning. However, open-label counterconditioning, in which participants are informed about the placebo content of the treatment, has not been investigated, while this can be highly relevant for clinical practice. Furthermore, (open-label) conditioning and counterconditioning has not been investigated for pain modalities relevant to musculoskeletal disorders, such as pressure pain. MethodsIn a randomized controlled trial, we investigated in 110 healthy female participants whether nocebo effects on pressure pain combined with open-label verbal suggestions can be (1) induced via conditioning and (2) reduced via counterconditioning. Participants were allocated to either a nocebo- or sham-conditioning group. Next, the nocebo group was allocated to either counterconditioning, extinction or continued nocebo conditioning; sham conditioning was followed by placebo conditioning. ResultsNocebo effects were significantly larger after nocebo conditioning than sham conditioning (d = 1.27). Subsequently, a larger reduction of the nocebo effect was found after counterconditioning than after extinction (d = 1.02) and continued nocebo conditioning (d = 1.66), with effects similar to placebo conditioning (following sham conditioning). ConclusionsThese results show that (counter)conditioning combined with open-label suggestions can modulate nocebo effects on pressure pain, which provides promise in designing learning-based treatments to reduce nocebo effects in patients with chronic pain disorders, particularly for musculoskeletal disorders. SignificanceFew studies have investigated the efficacy counterconditioning to reduce nocebo effects. Whereas typically deceptive procedures are used, these are not ethically appropriate for use in clinical practice. The current study demonstrates that open-label counterconditioning in a pain modality relevant for many chronic pain conditions may be a promising new strategy for reducing nocebo effects in a non-deceptive and ethical manner, which provides promise in designing learning-based treatments to reduce nocebo effects in patients with chronic pain disorders.
- 3 April 2023
- Published by Wiley in European journal of pain
- Vol. 27 (7) , 831-847
Open AccessEfficacy of open‐label counterconditioning for reducing nocebo effects on pressure pain
BackgroundNocebo effects can adversely affect the experience of physical symptoms, such as pain and itch. Nocebo effects on itch and pain have shown to be induced by conditioning with thermal heat stimuli and reduced by counterconditioning. However, open-label counterconditioning, in which participants are informed about the placebo content of the treatment, has not been investigated, while this can be highly relevant for clinical practice. Furthermore, (open-label) conditioning and counterconditioning has not been investigated for pain modalities relevant to musculoskeletal disorders, such as pressure pain. MethodsIn a randomized controlled trial, we investigated in 110 healthy female participants whether nocebo effects on pressure pain combined with open-label verbal suggestions can be (1) induced via conditioning and (2) reduced via counterconditioning. Participants were allocated to either a nocebo- or sham-conditioning group. Next, the nocebo group was allocated to either counterconditioning, extinction or continued nocebo conditioning; sham conditioning was followed by placebo conditioning. ResultsNocebo effects were significantly larger after nocebo conditioning than sham conditioning (d = 1.27). Subsequently, a larger reduction of the nocebo effect was found after counterconditioning than after extinction (d = 1.02) and continued nocebo conditioning (d = 1.66), with effects similar to placebo conditioning (following sham conditioning). ConclusionsThese results show that (counter)conditioning combined with open-label suggestions can modulate nocebo effects on pressure pain, which provides promise in designing learning-based treatments to reduce nocebo effects in patients with chronic pain disorders, particularly for musculoskeletal disorders. SignificanceFew studies have investigated the efficacy counterconditioning to reduce nocebo effects. Whereas typically deceptive procedures are used, these are not ethically appropriate for use in clinical practice. The current study demonstrates that open-label counterconditioning in a pain modality relevant for many chronic pain conditions may be a promising new strategy for reducing nocebo effects in a non-deceptive and ethical manner, which provides promise in designing learning-based treatments to reduce nocebo effects in patients with chronic pain disorders.
- Open Access
- 13 June 2022
- Published by Frontiers Media SA in Frontiers in Psychology
- Vol. 13, 806409
Counterconditioning as Treatment to Reduce Nocebo Effects in Persistent Physical Symptoms: Treatment Protocol and Study Design
Persistent physical symptoms have a high prevalence and a large impact for patients and society. To date, treatment effects for these symptoms are often limited. Nocebo effects (i.e., negative outcomes that are not attributable to active treatment components) have a substantial influence on treatment success and can be established via learning through classical conditioning. Therefore, interventions aimed at reducing nocebo effects by means of counterconditioning, in which an alternative association (inhibiting the previous association) is learned, could be a promising method for improving physical symptoms. In experimental studies, counterconditioning has been shown promising in reducing experimentally-induced nocebo effects on pain and itch. Application of counterconditioning procedures to reduce nocebo effects on clinical symptoms has yet to be researched. This paper provides a protocol of a 6-week counterconditioning intervention aimed at reducing nocebo effects and clinical pain in patients with fibromyalgia. A study in patients with fibromyalgia is proposed to examine the feasibility and potential effectiveness of this counterconditioning intervention as a novel treatment method for reducing nocebo effects and generalization to clinical pain symptoms. Results can help design an optimized treatment protocol for reducing nocebo effects, based on the experiences of participants and the first indications of treatment efficacy.
- 13 June 2022
- Published by Frontiers Media SA in Frontiers in Psychology
- Vol. 13, 806409
Open AccessCounterconditioning as Treatment to Reduce Nocebo Effects in Persistent Physical Symptoms: Treatment Protocol and Study Design
Persistent physical symptoms have a high prevalence and a large impact for patients and society. To date, treatment effects for these symptoms are often limited. Nocebo effects (i.e., negative outcomes that are not attributable to active treatment components) have a substantial influence on treatment success and can be established via learning through classical conditioning. Therefore, interventions aimed at reducing nocebo effects by means of counterconditioning, in which an alternative association (inhibiting the previous association) is learned, could be a promising method for improving physical symptoms. In experimental studies, counterconditioning has been shown promising in reducing experimentally-induced nocebo effects on pain and itch. Application of counterconditioning procedures to reduce nocebo effects on clinical symptoms has yet to be researched. This paper provides a protocol of a 6-week counterconditioning intervention aimed at reducing nocebo effects and clinical pain in patients with fibromyalgia. A study in patients with fibromyalgia is proposed to examine the feasibility and potential effectiveness of this counterconditioning intervention as a novel treatment method for reducing nocebo effects and generalization to clinical pain symptoms. Results can help design an optimized treatment protocol for reducing nocebo effects, based on the experiences of participants and the first indications of treatment efficacy.
- Open Access
- 11 May 2022
- Published by Center for Open Science in PsyArXiv
Nocebo hyperalgesia in patients with fibromyalgia and healthy controls: An experimental investigation of conditioning and extinction processes at baseline and one-month follow-up - Preprint
Nocebo effects are adverse treatment outcomes that are not ascribed to active treatment components. Potentially, their magnitude might be higher in chronic pain patients compared to healthy controls since patients likely experience treatment failure more frequently. The current study investigated group differences in the induction and extinction of conditioned nocebo effects on pressure pain at baseline (N= 69) and one-month follow-up (N= 56) in female patients with fibromyalgia and matched healthy controls. Nocebo effects were first experimentally induced via classical conditioning combined with instructions about the pain-increasing function of a sham TENS device, and then reduced via extinction. One month later, the same nocebo induction and reduction procedures were repeated to explore their stability. Our findings suggest an induction and reduction of nocebo effects in the healthy control group during baseline, with less clear evidence for these occurring in the patient group. During follow-up, nocebo effects were induced across both groups, but not reduced via extinction. 43% of all participants were nocebo responders in both sessions. Sensitivity analyses suggest that extinction was effective for nocebo responders in each session. Moreover, across all participants, the magnitudes of induced and reduced nocebo effects were stable between baseline and follow-up, without significant group effects over time. Our findings indicate that patients with fibromyalgia might be less responsive to the experimental manipulation of nocebo effects on pressure pain than healthy controls. Considering that nocebo responses are common in clinical settings, further investigation of conditioned nocebo effects is essential to minimize its role during treatment.
- 11 May 2022
- Published by Center for Open Science in PsyArXiv
Open AccessNocebo hyperalgesia in patients with fibromyalgia and healthy controls: An experimental investigation of conditioning and extinction processes at baseline and one-month follow-up - Preprint
Nocebo effects are adverse treatment outcomes that are not ascribed to active treatment components. Potentially, their magnitude might be higher in chronic pain patients compared to healthy controls since patients likely experience treatment failure more frequently. The current study investigated group differences in the induction and extinction of conditioned nocebo effects on pressure pain at baseline (N= 69) and one-month follow-up (N= 56) in female patients with fibromyalgia and matched healthy controls. Nocebo effects were first experimentally induced via classical conditioning combined with instructions about the pain-increasing function of a sham TENS device, and then reduced via extinction. One month later, the same nocebo induction and reduction procedures were repeated to explore their stability. Our findings suggest an induction and reduction of nocebo effects in the healthy control group during baseline, with less clear evidence for these occurring in the patient group. During follow-up, nocebo effects were induced across both groups, but not reduced via extinction. 43% of all participants were nocebo responders in both sessions. Sensitivity analyses suggest that extinction was effective for nocebo responders in each session. Moreover, across all participants, the magnitudes of induced and reduced nocebo effects were stable between baseline and follow-up, without significant group effects over time. Our findings indicate that patients with fibromyalgia might be less responsive to the experimental manipulation of nocebo effects on pressure pain than healthy controls. Considering that nocebo responses are common in clinical settings, further investigation of conditioned nocebo effects is essential to minimize its role during treatment.
- Open Access
- 22 December 2021
- Published by Center for Open Science in PsyArXiv
Efficacy of open-label counterconditioning for reducing nocebo effects on pressure pain
Nocebo effects can adversely affect the experience of physical symptoms, such as pain and itch. Nocebo effects on itch and pain have shown to be induced by conditioning with thermal heat stimuli and reduced by counterconditioning. However, open-label counterconditioning, in which participants are informed about the placebo content of the treatment, has not been investigated, while this can be highly relevant for clinical practice. Furthermore, (open-label) conditioning and counterconditioning has not been investigated for pain modalities relevant to musculoskeletal disorders, such as pressure pain. In a randomized controlled trial, we investigated in 110 healthy female participants whether nocebo effects on pressure pain combined with open-label verbal suggestions can be 1) induced via conditioning and 2) reduced via counterconditioning. Participants were allocated to either a nocebo or sham conditioning group. Next, the nocebo group was allocated to either counterconditioning, extinction, or continued nocebo conditioning; sham conditioning was followed by placebo conditioning. Nocebo effects were significantly larger after nocebo conditioning than sham conditioning (d = 1.27). Subsequently, a larger reduction of the nocebo effect was found after counterconditioning than after extinction (d = .99) and continued nocebo conditioning (d = 1.63), with effects similar to placebo conditioning (following sham conditioning). These results show that (counter)conditioning combined with open-label suggestions can modulate nocebo effects on pressure pain, which provides promise in designing learning-based treatments to reduce nocebo effects in patients with chronic pain disorders, particularly for musculoskeletal disorders.
- 22 December 2021
- Published by Center for Open Science in PsyArXiv
Open AccessEfficacy of open-label counterconditioning for reducing nocebo effects on pressure pain
Nocebo effects can adversely affect the experience of physical symptoms, such as pain and itch. Nocebo effects on itch and pain have shown to be induced by conditioning with thermal heat stimuli and reduced by counterconditioning. However, open-label counterconditioning, in which participants are informed about the placebo content of the treatment, has not been investigated, while this can be highly relevant for clinical practice. Furthermore, (open-label) conditioning and counterconditioning has not been investigated for pain modalities relevant to musculoskeletal disorders, such as pressure pain. In a randomized controlled trial, we investigated in 110 healthy female participants whether nocebo effects on pressure pain combined with open-label verbal suggestions can be 1) induced via conditioning and 2) reduced via counterconditioning. Participants were allocated to either a nocebo or sham conditioning group. Next, the nocebo group was allocated to either counterconditioning, extinction, or continued nocebo conditioning; sham conditioning was followed by placebo conditioning. Nocebo effects were significantly larger after nocebo conditioning than sham conditioning (d = 1.27). Subsequently, a larger reduction of the nocebo effect was found after counterconditioning than after extinction (d = .99) and continued nocebo conditioning (d = 1.63), with effects similar to placebo conditioning (following sham conditioning). These results show that (counter)conditioning combined with open-label suggestions can modulate nocebo effects on pressure pain, which provides promise in designing learning-based treatments to reduce nocebo effects in patients with chronic pain disorders, particularly for musculoskeletal disorders.